Market Place
Sourcing Support
Sobi completes acquisition of CTI BioPharma Corp.
26 Jun 2023 //
PR NEWSWIRE
In $1.7B buy, Sobi acquires CTI and myelofibrosis drug Vonjo
11 May 2023 //
FIERCE PHARMA
Sweden`s SOBI makes $1.7 bln offer to buy CTI BioPharma
10 May 2023 //
REUTERS
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 May 2023 //
PR NEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 May 2023 //
PR NEWSWIRE
CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023
12 Apr 2023 //
PR NEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Apr 2023 //
PR NEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Mar 2023 //
PR NEWSWIRE
CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
PR NEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Mar 2023 //
PR NEWSWIRE
CTI BioPharma to Present at the 43rd Annual Cowen Health Care Conference
01 Mar 2023 //
PR NEWSWIRE
CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
PR NEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Feb 2023 //
PR NEWSWIRE
CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023
02 Feb 2023 //
PR NEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 Jan 2023 //
PR NEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Dec 2022 //
PR NEWSWIRE
CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at ASH
11 Dec 2022 //
PRNEWSWIRE
CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit
30 Nov 2022 //
PRNEWSWIRE
CTI BioPharma Announces Presentation at the 2022 ASH Annual Meeting
03 Nov 2022 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 Sep 2022 //
PRNEWSWIRE
CTI Announces Presentation of Anemia Benefit Data from Pacritinib Program
21 Sep 2022 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Aug 2022 //
PRNEWSWIRE
CTI BioPharma Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Jun 2022 //
PRNEWSWIRE
CTI BioPharma Presents Pivotal Data from Pacritinib Program at EHA
10 Jun 2022 //
PRNEWSWIRE
CTI BioPharma to Present at Upcoming June Conferences
02 Jun 2022 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27 May 2022 //
PRNEWSWIRE
CTI BioPharma Presents Pivotal Data from Pacritinib Program at 2022 ASCO
26 May 2022 //
PRNEWSWIRE
CTI BioPharma Reports First Quarter 2022 Financial Results
12 May 2022 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 May 2022 //
PRNEWSWIRE
CTI BioPharma to Report First Quarter 2022 Financial Results on May 12, 2022
28 Apr 2022 //
PRNEWSWIRE
CTI BioPharma to Present at 21st Annual Needham Virtual Healthcare Conference
06 Apr 2022 //
PRNEWSWIRE
VONJO Approved for Myelofibrosis with Platelet Count Below 50 x 109/L
04 Mar 2022 //
BUSINESSWIRE
CTI BioPharma to Present at the Cowen 42nd Annual Healthcare Conference
02 Mar 2022 //
PRNEWSWIRE
CTI BioPharma Announces FDA Accelerated Approval of VONJO
28 Feb 2022 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Feb 2022 //
PRNEWSWIRE
CTI BioPharma Presents Data from Pacritinib Program
11 Dec 2021 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Nov 2021 //
PRNEWSWIRE
CTI BioPharma’s PRE-VENT Trial Misses Endpoint in Severe COVID
04 Oct 2021 //
CONTRACTPHARMA
CTI BioPharma’s PRE-VENT Trial Misses Endpoint in Severe COVID
04 Oct 2021 //
CONTRACTPHARMA
CTI BioPharma’s pacritinib fails to meet primary goal in Covid study
04 Oct 2021 //
CLINICALTRIALSARENA
CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors
24 Aug 2021 //
PRNEWSWIRE
CTI BioPharma to Report Second Quarter 2021 Financial Results on August 5, 2021
29 Jul 2021 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Jul 2021 //
PRNEWSWIRE
CTI BioPharma to Present at JMP Securities Life Sciences Conference on June 16
09 Jun 2021 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Jun 2021 //
PRNEWSWIRE
US FDA accepts and grants priority review to CTI BioPharma’s NDA for pacritinib
01 Jun 2021 //
PHARMABIZ
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Apr 2021 //
PRNEWSWIRE
CTI BioPharma Corp. Announces Proposed Public Offering of Common Stock
31 Mar 2021 //
PRNEWSWIRE
CTI BioPharma Announces Completion of Rolling Submission (NDA) for Pacritinib
31 Mar 2021 //
PRNEWSWIRE
CTI Announces Completion of Rolling Submission of (NDA) for Pacritinib
30 Mar 2021 //
PRNEWSWIRE
Phase 1 Trial Demonstrates Encouraging Clinical Benefit Promising Safety Profile
22 Mar 2021 //
PRNEWSWIRE
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Mar 2021 //
PRNEWSWIRE
CTI BioPharma Announces Presentation of Data Supporting Pacritinib
07 Dec 2020 //
PRNEWSWIRE
CTI Announces Publication of Article Highlighting Pacritinib Data from PAC203
30 Nov 2020 //
PRNEWSWIRE
CTI BioPharma Announces Publication of Article Highlighting Pacritinib
30 Nov 2020 //
PRNEWSWIRE
CTI Announces Oral Presentation at the 62nd American Society of Hematology
04 Nov 2020 //
PRNEWSWIRE
CTI BioPharma Initiates Rolling SNDA for Pacritinib in Myelofibrosis Patients
13 Oct 2020 //
PRNEWSWIRE
CTI BioPharma Initiates Rolling Submission of (NDA) for Pacritinib
13 Oct 2020 //
BIOSPACE
CTI BioPharma sees analysts price targets rising on FDA accelerated approval
30 Sep 2020 //
SEEKING ALPHA
